Real-world data of MDS and CMML in Japan : results of JALSG clinical observational study-11 (JALSG-CS-11)
© 2023. Japanese Society of Hematology..
We conducted a multicenter, prospective observational study of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML) in Japan. From August 2011 to January 2016, we enrolled 6568 patients. Herein, we report the results for MDS (n = 2747) and CMML (n = 182). The percentage of patients aged 65 years or older was 79.5% for MDS and 79.7% for CMML. The estimated overall survival (OS) rate and cumulative incidence of AML evolution at 5 years were 32.3% (95% confidence interval: 30.2-34.5%) and 25.7% (23.9-27.6%) for MDS, and 15.0% (8.9-22.7%) and 39.4% (31.1-47.6%) for CMML. Both diseases were more common in men. The most common treatment for MDS was azacitidine, which was used in 45.4% of higher-risk and 12.7% of lower-risk MDS patients. The 5-year OS rate after treatment with azacitidine was 12.1% (9.5-15.1%) for of higher-risk MDS patients and 33.9% (25.6-42.4%) for lower-risk patients. The second most common treatment was erythropoiesis-stimulating agents, given to just 20% of lower-risk patients. This is the first paper presenting large-scale, Japanese data on survival and clinical characteristics in patients with MDS and CMML.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:119 |
|---|---|
| Enthalten in: |
International journal of hematology - 119(2024), 2 vom: 01. Feb., Seite 130-145 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Usuki, Kensuke [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.02.2024 Date Revised 01.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12185-023-03686-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365819557 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365819557 | ||
| 003 | DE-627 | ||
| 005 | 20240201232044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12185-023-03686-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1277.xml |
| 035 | |a (DE-627)NLM365819557 | ||
| 035 | |a (NLM)38091231 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Usuki, Kensuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world data of MDS and CMML in Japan |b results of JALSG clinical observational study-11 (JALSG-CS-11) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2024 | ||
| 500 | |a Date Revised 01.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Japanese Society of Hematology. | ||
| 520 | |a We conducted a multicenter, prospective observational study of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML) in Japan. From August 2011 to January 2016, we enrolled 6568 patients. Herein, we report the results for MDS (n = 2747) and CMML (n = 182). The percentage of patients aged 65 years or older was 79.5% for MDS and 79.7% for CMML. The estimated overall survival (OS) rate and cumulative incidence of AML evolution at 5 years were 32.3% (95% confidence interval: 30.2-34.5%) and 25.7% (23.9-27.6%) for MDS, and 15.0% (8.9-22.7%) and 39.4% (31.1-47.6%) for CMML. Both diseases were more common in men. The most common treatment for MDS was azacitidine, which was used in 45.4% of higher-risk and 12.7% of lower-risk MDS patients. The 5-year OS rate after treatment with azacitidine was 12.1% (9.5-15.1%) for of higher-risk MDS patients and 33.9% (25.6-42.4%) for lower-risk patients. The second most common treatment was erythropoiesis-stimulating agents, given to just 20% of lower-risk patients. This is the first paper presenting large-scale, Japanese data on survival and clinical characteristics in patients with MDS and CMML | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AML evolution | |
| 650 | 4 | |a Chronic myelomonocytic leukemia | |
| 650 | 4 | |a Epidemiology | |
| 650 | 4 | |a Myelodysplastic syndromes | |
| 650 | 4 | |a Survival | |
| 650 | 7 | |a Antimetabolites, Antineoplastic |2 NLM | |
| 650 | 7 | |a Azacitidine |2 NLM | |
| 650 | 7 | |a M801H13NRU |2 NLM | |
| 700 | 1 | |a Ohtake, Shigeki |e verfasserin |4 aut | |
| 700 | 1 | |a Honda, Sumihisa |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuda, Mitsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Wakita, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Nawa, Yuichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Takase, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Akio |e verfasserin |4 aut | |
| 700 | 1 | |a Sezaki, Nobuo |e verfasserin |4 aut | |
| 700 | 1 | |a Yokoyama, Hisayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Takada, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Hirano, Daiki |e verfasserin |4 aut | |
| 700 | 1 | |a Tomikawa, Tatsuki |e verfasserin |4 aut | |
| 700 | 1 | |a Sumi, Masahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yano, Shingo |e verfasserin |4 aut | |
| 700 | 1 | |a Handa, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ota, Shuichi |e verfasserin |4 aut | |
| 700 | 1 | |a Fujita, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Fujimaki, Katsumichi |e verfasserin |4 aut | |
| 700 | 1 | |a Mugitani, Atsuko |e verfasserin |4 aut | |
| 700 | 1 | |a Kojima, Kensuke |e verfasserin |4 aut | |
| 700 | 1 | |a Kajiguchi, Tomohiro |e verfasserin |4 aut | |
| 700 | 1 | |a Fujimoto, Ko |e verfasserin |4 aut | |
| 700 | 1 | |a Asou, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Usui, Noriko |e verfasserin |4 aut | |
| 700 | 1 | |a Ishikawa, Yuichi |e verfasserin |4 aut | |
| 700 | 1 | |a Katsumi, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumura, Itaru |e verfasserin |4 aut | |
| 700 | 1 | |a Miyazaki, Yasushi |e verfasserin |4 aut | |
| 700 | 1 | |a Kiyoi, Hitoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of hematology |d 1997 |g 119(2024), 2 vom: 01. Feb., Seite 130-145 |w (DE-627)NLM012627607 |x 1865-3774 |7 nnns |
| 773 | 1 | 8 | |g volume:119 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:130-145 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12185-023-03686-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 119 |j 2024 |e 2 |b 01 |c 02 |h 130-145 | ||